Artiva Biotherapeutics, Inc. Common Stock (ARTV) - Net Assets
Based on the latest financial reports, Artiva Biotherapeutics, Inc. Common Stock (ARTV) has net assets worth $129.22 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($148.86 Million) and total liabilities ($19.64 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset allocation strategy of Artiva Biotherapeutics, Inc. Common Stoc to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $129.22 Million |
| % of Total Assets | 86.81% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Artiva Biotherapeutics, Inc. Common Stock - Net Assets Trend (2019–2024)
This chart illustrates how Artiva Biotherapeutics, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see market value of Artiva Biotherapeutics, Inc. Common Stoc.
Annual Net Assets for Artiva Biotherapeutics, Inc. Common Stock (2019–2024)
The table below shows the annual net assets of Artiva Biotherapeutics, Inc. Common Stock from 2019 to 2024. Also explore Artiva Biotherapeutics, Inc. Common Stoc (ARTV) net asset momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $186.64 Million | +215.20% |
| 2023-12-31 | $-162.01 Million | -15.15% |
| 2022-12-31 | $-140.70 Million | -58.34% |
| 2021-12-31 | $-88.86 Million | -312.01% |
| 2020-12-31 | $-21.57 Million | -444.62% |
| 2019-12-31 | $-3.96 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Artiva Biotherapeutics, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 24269700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $3.00K | 0.00% |
| Other Comprehensive Income | $-129.00K | -0.07% |
| Other Components | $433.45 Million | 232.24% |
| Total Equity | $186.64 Million | 100.00% |
Artiva Biotherapeutics, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Artiva Biotherapeutics, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Conrad Asia Energy Ltd
AU:CRD
|
$82.88 Million |
|
True North Commercial Real Estate Investment Trust
TO:TNT-UN
|
$82.92 Million |
|
Orthex Oyj
HE:ORTHEX
|
$82.93 Million |
|
Fairchem Organics Limited
NSE:FAIRCHEMOR
|
$82.94 Million |
|
SHEPHERD NEAME P. CONS.
F:43Y
|
$82.80 Million |
|
Lithium Ionic Corp
V:LTH
|
$82.78 Million |
|
Petrovietnam Low Pressure Gas Distribution JSC
VN:PGD
|
$82.75 Million |
|
Southern Concrete Pile PCL
BK:SCP
|
$82.71 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Artiva Biotherapeutics, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -162,015,000 to 186,641,000, a change of 348,656,000.
- Net loss of 58,493,000 reduced equity.
- Share repurchases of 4,183,000 reduced equity.
- New share issuances of 166,507,000 increased equity.
- Other comprehensive income decreased equity by 437,000.
- Other factors increased equity by 245,262,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-58.49 Million | -31.34% |
| Share Repurchases | $4.18 Million | -2.24% |
| Share Issuances | $166.51 Million | +89.21% |
| Other Comprehensive Income | $-437.00K | -0.23% |
| Other Changes | $245.26 Million | +131.41% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Artiva Biotherapeutics, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.16x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $-1.23 | $8.91 | x |
| 2021-12-31 | $-5.05 | $8.91 | x |
| 2022-12-31 | $-8.00 | $8.91 | x |
| 2023-12-31 | $-6.96 | $8.91 | x |
| 2024-12-31 | $7.66 | $8.91 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Artiva Biotherapeutics, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -31.34%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -23303.98%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.12x
- Recent ROE (-31.34%) is below the historical average (-6.27%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-15.83 Million |
| 2021 | 0.00% | -3587.66% | 0.01x | 0.00x | $-62.94 Million |
| 2022 | 0.00% | -1184.10% | 0.04x | 0.00x | $-44.32 Million |
| 2023 | 0.00% | -82.69% | 0.32x | 0.00x | $-11.49 Million |
| 2024 | -31.34% | -23303.98% | 0.00x | 1.12x | $-77.16 Million |
Industry Comparison
This section compares Artiva Biotherapeutics, Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $161,895,707
- Average return on equity (ROE) among peers: -42.53%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Artiva Biotherapeutics, Inc. Common Stock (ARTV) | $129.22 Million | 0.00% | 0.15x | $82.80 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $109.30 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $2.99 Billion |
| Abeona Therapeutics Inc (ABEO) | $170.10 Million | -16.06% | 0.05x | $310.51 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-11.42 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-12.35 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $1.35 Billion |
| Arbutus Biopharma Corp (ABUS) | $38.29 Million | -30.60% | 0.11x | $906.70 Million |
| ABVC Biopharma Inc (ABVC) | $2.46 Million | -172.46% | 1.68x | $28.25 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.66 Million | -45.66% | 0.56x | $9.31 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $199.76 Million | -82.32% | 0.11x | $4.61 Billion |
About Artiva Biotherapeutics, Inc. Common Stock
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus n… Read more